Osteoprotegerin in sputum is a potential biomarker in COPD

Chest

Volumn 140, Issue 1, 2011, Pages 76-83

  To, Masako ^a   Ito, Kazuhiro ^a   Ausin, Pilar M ^a   Kharitonov, Sergei A ^a   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; GELATINASE B; INTERLEUKIN 8; OSTEOPROTEGERIN;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; GAS DIFFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FUNCTION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESIDUAL VOLUME; SMOKING; SPUTUM LEVEL; TOTAL LUNG CAPACITY;

EID: 79960418124     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-1608     Document Type: Article

References (34)

1. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672-688. (Pubitemid 37258549)
2. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56(4):515-548. (Pubitemid 39658462)
3. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-192. (Pubitemid 351323287)
4. Nakano Y, Sakai H, Muro S, et al. Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: incidence and contribution to lung function. Thorax. 1999;54(5):384-389. (Pubitemid 29199774)
5. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med. 2000;162(3 pt 1):1102-1108.
6. Lee YK, Oh YM, Lee JH, et al; KOLD Study Group. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung. 2008;186(3):157-165.
7. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597-3602.
8. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139(3): 1329-1337. (Pubitemid 28510154)
9. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62(6):1619-1623. (Pubitemid 34408480)
10. Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol. 2006;42(4):415-420.
11. Miyashita T, Kawakami A, Nakashima T, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol. 2004;137(2):430-436. (Pubitemid 39013092)
12. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;275(28):20959-20962. (Pubitemid 30481782)
13. Maruyama K, Takada Y, Ray N, et al. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol. 2006; 177(6):3799-3805. (Pubitemid 44359913)
14. Crisafulli A, Micari A, Altavilla D, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci(Lond). 2005;109(4): 389-395. (Pubitemid 41445246)
15. Hermann-Arnhof KM, Kästenbauer T, Publig T, et al. Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting. Crit Care Med. 2006;34(1):76-80. (Pubitemid 43032382)
16. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106(10):1192-1194. (Pubitemid 34988634)
17. Rhee EJ, Lee WY, Kim SY, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond). 2005;108(3):237-243.
18. Buzi F, Maccarinelli G, Guaragni B, et al. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin Endocrinol (Oxf). 2004;60(1):87-91.
19. Feuerherm AJ, Borset M, Seidel C, et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol. 2001;30(4): 229-234. (Pubitemid 32762861)
20. Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A. Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. Ann Rheum Dis. 2004;63(2):216-217. (Pubitemid 38122149)
21. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum. 2002;46(7): 1744-1753. (Pubitemid 34774505)
22. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab. 2001;86(7):3162-3165. (Pubitemid 32673481)
23. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14(4):518-527. (Pubitemid 29153384)
24. Yamashita T, Okada S, Higashio K, Nabeshima Y, Noda M. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. Endocrinology. 2002;143(12): 4711-4717. (Pubitemid 35397613)
25. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Web site. www.goldcopd.org. Updated 2007. Accessed June 10, 2010.
26. National Institute of Health, National Heart, Lung, and Blood Institute. Global Strategy for Asthma Manage ment and Prevention. Updated 2005. Bethesda, MD: National Institutes of Health; 2005. NIH/NHLBI publication 95-3659.
27. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
28. Ding L, Quinlan KB, Elliott WM, et al. A lung tissue bank for gene expression studies in chronic obstructive pulmonary disease. COPD. 2004;1(2):191-204.
29. Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD cohort study. Eur Respir J. 2010;35(3):540-548.
30. Punturieri A, Filippov S, Allen E, et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med. 2000;192(6):789-799.
31. Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol. 2002;283(4):L867-L873.
32. Wittrant Y, Couillaud S, Theoleyre S, Dunstan C, Heymann D, Rédini F. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun. 2002;293(1):38-44. (Pubitemid 34694167)
33. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inacti vation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol. 2006;26(9):2117-2124. (Pubitemid 44253797)
34. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005;111(23): 3119-3125. (Pubitemid 40847790)